Frontiers in Immunology
Case Report: Nicotinamide monotherapy for infantile bullous pemphigoid with long-term follow-up
By Peng Qu, Guizhi Zhou and Baoqi Yang.
Abstract
Infantile bullous pemphigoid (IBP) is a rare autoimmune bullous skin disease that occurs in infants, for which standardized targeted therapeutic regimens remain unavailable. Herein, we report two infants with IBP treated with nicotinamide monotherapy. Complete clinical remission was observed within 3 weeks and 10 days after treatment initiation, respectively. Following clinical improvement, nicotinamide was gradually tapered and discontinued in approximately 2 months. No recurrence was observed during long-term follow-up. However, given the limited number of cases, these observations do not establish the therapeutic efficacy of nicotinamide but provide clinical experience with nicotinamide monotherapy in IBP.
Keywords
- Autoimmune Bullous Skin Diseases
- Nicotinamide
- Bullous pemphigoid
- Niacinamide
- Disease
- Nicotinamide phosphoribosyltransferase
- Therapeutic approach
- Open access
Source
Published in Frontiers in Immunology. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.